Physiomics plc (LSE:PYC) has entered into a new engagement with Numab Therapeutics AG to aid in the pre-clinical progress of a multi-specific antibody aimed at treating autoimmune disorders. Under this partnership, Physiomics will design a mechanistic PK/PD model to better characterize how the therapy behaves in the body and to guide dose-selection strategies for both early-stage and future clinical trials. The initiative underscores the growing importance of Model-Informed Drug Development and further positions Physiomics as a key contributor to antibody program advancement across oncology and autoimmune pipelines.
Despite developments on the operational front, Physiomics continues to face substantial financial headwinds. Revenue contraction, persistent losses, and weak technical signals all point to a challenging near-term outlook. Although recent strategic moves could support longer-term growth, valuation pressures and ongoing financial instability remain core concerns.
More about Physiomics
Physiomics plc specializes in mathematical modelling, data analytics, and biostatistics to support the creation of new therapies and personalized medicine approaches. By applying Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics, the company assists pharmaceutical and biotech organizations in refining drug development strategies, mitigating risk, and improving study design from early discovery through clinical testing. The firm has worked on more than 100 commercial assignments and maintains collaborations with recognized industry partners including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and Cancer Research UK.
Leave a Reply